A study evaluating the improvement of proptosis of patients who have received teprotumumab, and a sustained expression of IGF-1R in orbital tissues from patients with non-inflammatory TED compared to normal controls
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
Most Recent Events
- 05 Oct 2021 New trial record
- 01 Sep 2021 Results published in the Eye